FDA CRL rejecting deramiocel on data integrity sinks Capricor 70% after hours
- FDA posted Nov. 20 statement issuing a complete response letter for the deramiocel BLA.
- Agency said HOPE-3 data are unreliable due to serious integrity violations that cannot be fixed.
- BIMO inspection found unauthorized SAP changes, blinding breaches and other protocol issues.
- Evidence failed the approval standard even after the major amendment and July AdCom.
- PDUFA target was Nov. 22; FDA released the decision early on Friday after the close.
- Regular session closed +0.8% at about $7.59 before the after-hours collapse to $2.29.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.